VMI
PTGX icon

VHCP Management III’s Protagonist Therapeutics PTGX Stock Holding History

VHCP Management III’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$571K Sell
80,929
-991,419
-92% -$9.85M 0.11% 17
2019
Q3 		$12.9M Hold
1,072,348
– – 7.95% 5
2019
Q2 		$13M Buy
1,072,348
+263,025
+32% +$2.91M 6.06% 6
2019
Q1 		$10.2M Buy
809,323
+386,147
+91% +$3.41M 5.93% 8
2018
Q4 		$2.85M Buy
+423,176
New +$3.36M 2.07% 11

Other funds holding PTGX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

VHCP Management III's PTGX Position: Q4 2019 in Review

VHCP Management III reduced its Protagonist Therapeutics (PTGX) stake by 92% in Q4 2019, selling an estimated $9.85M and leaving 80,929 shares worth $571K. The position accounts for 0.11% of the portfolio, ranked #17.

VHCP Management III first reported a position in PTGX in Q4 2018 and has held it in 5 quarters since. The position peaked at $13M in Q2 2019. 81 funds tracked by Wall St. Rank hold PTGX as of Q4 2019.

  • VHCP Management III held 80,929 shares of Protagonist Therapeutics worth $571K as of Q4 2019.
  • VHCP Management III sold 991,419 Protagonist Therapeutics shares in Q4 2019, an estimated $9.85M.
  • Protagonist Therapeutics made up 0.11% of VHCP Management III's portfolio in Q4 2019, its #17 holding.
  • VHCP Management III first reported a position in Protagonist Therapeutics in Q4 2018 and has held it in 5 quarters since.
  • VHCP Management III's Protagonist Therapeutics position peaked at $13M in Q2 2019.
  • 81 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q4 2019.

Based on VHCP Management III's 13F filing for Q4 2019, filed 13 Feb 2020.